# US 2023/0405140 A1 · Anti-cd56 antibody-drug conjugates and their use in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405140 A1
- Document ID: US20230405140A1
- Status: Published application
- Kind: A1
- Application number: 18/333,261
- Filed: 2023-06-12
- Published: 2023-12-21
- Earliest claimed: 2020-02-27
- Applicants: Mcsaf Inside Oncology
- Inventors: Ludovic JUEN; Christine BALTUS; Audrey DESGRANGES; Antoine TOUZÉ; Thibault KERVARREC; Valérie LEBLOND; Mahtab SAMIMI
- Web page: https://patentgrep.com/patent/US20230405140A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6865: {the tumour determinant being from skin, nerves or brain cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to antibody-drug conjugates and to their use in therapy, in particular for treating CD56+ cancers.

## Claims

### Claim 1

An anti-CD56 antibody-drug conjugate (ADC) comprising an anti-CD56 antibody and a drug conjugate, wherein the ADC has one or more effective functions mediated by an Fc portion of the anti-CD56 antibody attenuated, wherein the one or more effective functions mediated by the Fc portion are selected from ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) and CDC (Complement-Dependent Cytotoxicity).

### Claim 2 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, comprising a mutation of Fc portion of the anti-CD56 antibody.

### Claim 3 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, comprising a mutation of the Fc portion that reduces the effective functions mediated by the Fc portion of the anti-CD56 antibody.

### Claim 4 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, comprising a mutation of the Fc portion that aims at deglycosylating the Fc portion of the anti-CD56 antibody.

### Claim 5 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, comprising a mutation of the Fc portion of the ant-CD56 antibody that aims at suppressing glycosylation at asparagine 297.

### Claim 6

An anti-CD56 antibody-drug conjugate (ADC) comprising a Fc portion, wherein said Fc portion does not carry a glycosylation.

### Claim 7 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, wherein the amino acid sequence of the anti-CD56 antibody comprises a mutation aimed at deglycosylating the Fc portion of said anti-CD56 antibody.

### Claim 8 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, wherein the amino acid sequence of the anti-CD56 antibody comprises a mutation aimed at suppressing glycosylation at asparagine 297.

### Claim 9 (depends on 1)

The anti-CD56 antibody as claimed in claim 1, wherein the anti-CD56 antibody does not carry a glycosylation at asparagine 297.

### Claim 10 (depends on 1)

The anti-CD56 antibody as claimed in claim 1, wherein the amino acid sequence of the anti-CD56 antibody comprises a substitution of asparagine 297 with alanine.

### Claim 11 (depends on 1)

The anti-CD56 ADC as claimed in claim 1, wherein the antibody is an IgG antibody.

### Claim 12 (depends on 1)

The anti-CD56 antibody-drug conjugate according to claim 1, having the following formula (I):
in which:
A is an anti-CD56 antibody or an antibody fragment;
the attachment head is represented by one of the following formulae:
the linker is a cleavable linker represented by the following formula:
the spacer is represented by the following formula:
m is an integer from 1 to 10;
n is an integer from 1 to 4.

### Claim 13 (depends on 1)

The antibody-drug conjugate as claimed in claim 1, in which the cytotoxic drug is selected from methotrexate, IMIDs, duocarmycin, combretastatin, calicheamicin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), maytansine, DM1, DM4, SN38, amanitin, pyrrolobenzodiazepine, pyrrolobenzodiazepine dimer, pyrrolopyridodiazepine, pyrrolopyridodiazepine dimer, an inhibitor of histone deacetylase, an inhibitor of tyrosine kinase, and ricin, preferably MMAE.

### Claim 14 (depends on 1)

The antibody-drug conjugate as claimed in claim 1, having the following formula:

### Claim 15 (depends on 1)

The antibody-drug conjugate as claimed in claim 1, in which the anti-CD56 antibody is m906.

### Claim 16 (depends on 1)

The antibody-drug conjugate as claimed in claim 1, with the following formula (Ia):
or with the following formula (Ia′):

### Claim 17 (depends on 1)

A composition comprising one or more antibody-drug conjugate(s) as claimed in claim 1.

### Claim 18 (depends on 17)

The composition as claimed in claim 17, further comprising paclitaxel, docetaxel, doxorubicin and/or cyclophosphamide, lenalidomide, dexamethasone, carboplatin, etoposide and/or an antibody used in anti-cancer immunotherapy such as an anti-PD1 or an anti-PD-L1.

### Claim 19 (depends on 1, 17)

A method of treating a CD56+ cancer in a subject in need thereof comprising administering to the subject an anti-CD56 antibody drug conjugate (ADC) according to claim 1 or a composition according to claim 17.

### Claim 20 (depends on 19)

The method of treatment as claimed in claim 19, wherein the CD56+ cancer is selected from the group consisting of melanoma, blastemal tumors, hemopathies such as acute myeloid leukemias, myelomas, blastic plasmacytoid dendritic cell neoplasms and neuroendocrinal carcinomas.

### Claim 21 (depends on 19)

The method of treatment as claimed in claim 19, wherein the CD56+ cancer is a neuroendocrine carcinomas selected from the group consisting ofsmall cell lung carcinoma, neuroblastoma or Merkel cell carcinoma, preferably Merkel cell carcinoma.
